Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 4,244 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Knee Osteoarthritis
Interventions: Ketorolac, Betamethasone; Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years and older · Male only
Enrollment: 448 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Asthma
Interventions: Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more

Conditions: Low Back Pain
Interventions: Hydromorphone ER, Sugar pill; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peripheral Arterial Disease
Interventions: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter, EverCross Percutaneous Transluminal Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 42
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 37 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 19 more

Conditions: Gut Microbiome
Interventions: Dietary MACs, Control; Dietary Supplement · Other
Lead sponsor: Access Business Group; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions: Megestrol Acetate, iKanEat Behavioral Intervention; Drug · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 9 Months to 108 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Alvimopan, Placebo; Drug
Lead sponsor: Jamie N. Bakkum-Gamez; Other
Eligibility: 18 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Light Chain (AL) Amyloidosis
Interventions: Birtamimab, Placebo, Standard of Care Chemotherapy; Drug · Other
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 22
States / cities: North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more

Conditions: Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pelabresib, Ruxolitinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more

Conditions: Smoking Cessation
Interventions: Integrated Smoking Cessation and Financial Counseling, Waitlist Integrated Smoking Cessation and Financial Counseling, Nicotine Replacement Therapy (NRT); Behavioral · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV-2 Infection
Interventions: BTL-TML-COVID, Placebo; Drug
Lead sponsor: Beech Tree Labs, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Draper, Utah

Conditions: Retinal Detachment
Interventions: denufosol tetrasodium (INS37217) Intravitreal Injection; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 33
States / cities: Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Acute Ischemic Stroke
Interventions: PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT); Biological
Lead sponsor: Prolong Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Allergic Rhinitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control; Biological · Other
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Asthma
Interventions: PL-3994; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cranbury, New Jersey

Conditions: Type 1 Diabetes
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Gainesville, Florida • Chicago, Illinois • Maywood, Illinois

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Alzheimer Disease
Interventions: Simufilam, Placebo; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 87 Years
Enrollment: 1,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more

Conditions: Dyspepsia, Helicobacter Pylori Infection
Interventions: RHB-105, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Chino, California • Jupiter, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: IP, Matching Placebo; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hyperkalemia
Interventions: RDX013, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more

Conditions: Postoperative Pain
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon

Diagnosing Epilepsy To EffeCT Change

Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

Accelerating Gastrointestinal Recovery

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Intravenous Acetaminophen in Craniotomy